CoChat

Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer

Open access
Pipe, Steven, Leebeek, Frank W.G., Ferreira, Valerie, Sawyer, Eileen K., Pasi, John · 2019 · Molecular Therapy - Methods & Clinical Development
Cited by 92

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

As gene transfer with adeno-associated virus (AAV) vectors is starting to enter clinical practice, this review examines the impact of vector capsid choice in liver-directed gene transfer for hemophilia. Given that there are multiple clinical trials completed and ongoing in this field, it is important to review the clinical evidence, particularly as a range of AAV-vector serotypes including AAV2, AAV5, AAV8, and AAV10 have been tested. Although there have been a number of successful trials, the development of two investigational AAV vectors for hemophilia B has been discontinued because they did not meet efficacy and/or safety expectations. Whether this difference between success and failure of gene transfer approaches reflects capsid choice, vector design, manufacturing system, or other variables is a question of great interest. Here, we examine the body of evidence across trials to determine the possible influences of serotype choice on key clinical outcomes such as safety, vector clearance, treatment eligibility, occurrence of transaminase elevations, activation of capsid-directed cytotoxic T cell responses, and clinical efficacy. In summary, gene transfer requires a balance between achieving sufficient transgene expression and minimizing destructive immune responses, which may be affected by AAV-vector serotype choice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2019.08.015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 29

  1. Morrison, 2017, Landmark gene therapy poised for US approval, Nat. Rev. Drug Discov., 16, 739, 10.1038/nrd.2017.212 · doi:10.1038/nrd.2017.212
  2. Wang, 2010, Systematic evaluation of AAV vectors for liver directed gene transfer in murine models, Mol. Ther., 18, 118, 10.1038/mt.2009.246 · DOI · Paper page
  3. Greig, 2018, Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. Hum, Gene Ther., 10.1089/hum.2018.080 · DOI
  4. Mitchell, 2010, AAV’s anatomy: roadmap for optimizing vectors for translational success, Curr. Gene Ther., 10, 319, 10.2174/156652310793180706 · DOI · Paper page
  5. Drouin, 2013, Adeno-associated virus structural biology as a tool in vector development, Future Virol., 8, 1183, 10.2217/fvl.13.112 · DOI · Paper page
  6. Maurer, 2018, The Assembly-Activating Protein Promotes Stability and Interactions between AAV’s Viral Proteins to Nucleate Capsid Assembly, Cell Rep., 23, 1817, 10.1016/j.celrep.2018.04.026 · DOI · Paper page
  7. Tseng, 2014, Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors, Front. Immunol., 5, 9, 10.3389/fimmu.2014.00009 · DOI · Paper page
  8. Nam, 2007, Structure of adeno-associated virus serotype 8, a gene therapy vector, J. Virol., 81, 12260, 10.1128/JVI.01304-07 · DOI · Paper page
  9. Srivastava, 2016, In vivo tissue-tropism of adeno-associated viral vectors, Curr. Opin. Virol., 21, 75, 10.1016/j.coviro.2016.08.003 · DOI · Paper page
  10. Pillay, 2017, AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR, J. Virol., 10.1128/JVI.00391-17 · DOI · Paper page
  11. Ling, 2010, Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3, Hum. Gene Ther., 21, 1741, 10.1089/hum.2010.075 · DOI · Paper page
  12. Wu, 2006, Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes, J. Virol., 80, 11393, 10.1128/JVI.01288-06 · DOI · Paper page
  13. Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
  14. Davidoff, 2005, Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models, Mol. Ther., 11, 875, 10.1016/j.ymthe.2004.12.022 · DOI · Paper page
  15. Gao, 2006, Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates, Mol. Ther., 13, 77, 10.1016/j.ymthe.2005.08.017 · DOI · Paper page
  16. Salmon, 2014, Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®), Expert Rev. Clin. Pharmacol., 7, 53, 10.1586/17512433.2014.852065 · DOI · Paper page
  17. Rajasekaran, 2018, Infectivity of adeno-associated virus serotypes in mouse testis, BMC Biotechnol., 18, 70, 10.1186/s12896-018-0479-1 · DOI
  18. Majowicz, 2017, Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1, Mol. Ther., 25, 1831, 10.1016/j.ymthe.2017.05.003 · DOI · Paper page
  19. High, 2014, Gene therapy for hemophilia: the clot thickens, Hum. Gene Ther., 25, 915, 10.1089/hum.2014.2541 · DOI
  20. D’Avola, 2016, Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol., 65, 776, 10.1016/j.jhep.2016.05.012 · DOI · Paper page
  21. Majowicz, 2017, Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human Primates, Mol. Ther., 25, 94
  22. Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
  23. Chiorini, 1999, Cloning and characterization of adeno-associated virus type 5, J. Virol., 73, 1309, 10.1128/JVI.73.2.1309-1319.1999 · DOI · Paper page
  24. Akache, 2006, The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9, J. Virol., 80, 9831, 10.1128/JVI.00878-06 · DOI · Paper page
  25. Bell, 2012, Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid, J. Virol., 86, 7326, 10.1128/JVI.00448-12 · DOI · Paper page
  26. Pipe, 2017, 101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX), Blood, 130, 3331
  27. Monahan, 2015, Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B, J. Thromb. Haemost., 13, 87
  28. Long, 2017, Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A, Blood, 130, 3332
  29. Calcedo, 2017, Immune Responses in 101HEMB01, a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Severe Hemophilia B, Blood, 130, 3333

Cited by

Metadata

Authors
Pipe, S., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2019-12
Volume
15
Pages
170-178
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2972588675
Cited by
92
References
30
FWCI
5.69
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Catalyst Biosciences
  • Novo Nordisk
  • CSL Behring
  • Shire
  • Spark Therapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.